menu_open Columnists
We use cookies to provide some features and experiences in QOSHE

More information  .  Close

After its entire board resigned overnight, 23andMe will cut over 200 employees and its cancer research in an urgent bid to nurse the company back to health

3 1
12.11.2024
The DNA-testing firm said in a Tuesday SEC filing, “there is substantial doubt about the company’s ability to continue.”

© Fortune


Get it on Google Play